IntriCon Reports 2013 Second-Quarter Results

IntriCon Reports 2013 Second-Quarter Results

Global Restructuring Efforts Redirect Resources to Key Growth Opportunities, Drive Savings and Anticipated Profitability in Second-Half

ARDEN HILLS, Minn.--(BUSINESS WIRE)-- IntriCon Corporation (Nasdaq: IIN), a designer, developer, manufacturer and distributor of miniature and micro-miniature body-worn devices, today announced financial results for its second quarter ended June 30, 2013.

For the 2013 second quarter, the company reported net sales of $11.5 million, versus $14.9 million in the prior-year period. IntriCon had a net loss of $(3.4) million, or $(0.60) per diluted share, compared to a net loss of $(82,000), or $(0.01) per diluted share, for the 2012 second quarter.

The company reported a second-quarter net loss from continuing operations of $(2.0) million, or $(0.34) per diluted share. Second-quarter results from discontinued operations include a net loss of $(1.5) million, or $(0.26) per diluted share. Included in the $(1.5) million net loss from discontinued operations was approximately $(1.0) million, or $(0.18) per diluted share, of one-time, non-cash charges related to the restructuring initiatives.

In June 2013, IntriCon announced a global strategic restructuring plan designed to accelerate the company's future growth by focusing resources on the highest-potential growth areas and reduce costs by approximately $3.0 million annually. As a result, IntriCon's Maine operations, which include the company's security, certain microphone and receivers businesses, as well as certain Singapore assets, are now held for sale and classified as discontinued operations.

"Facing a shortfall in the second quarter, we moved quickly to implement our global restructuring plan to better align our cost structure with current lower revenue levels—and strategic focus," said Mark S. Gorder, president and chief executive officer of IntriCon. "We expect to see an immediate $2 million in annual cost savings in the third quarter, and we anticipate we will achieve an additional $1 million by the end of the year.

"We believe that these savings, combined with an anticipated rebound in medical and hearing health sales in the second half of the year, will allow us to achieve anticipated profitability from continuing operations in the 2013 fourth quarter."

As a percentage of total second-quarter sales, hearing health stood at 43.4 percent, with medical and professional audio at 42.6 percent and 14.0 percent, respectively. This compares to 41.5 percent, 41.4 percent and 17.1 percent for hearing health, medical and professional audio, respectively, in 2012.

Gross profit margins decreased to 16.2 percent from 25.2 percent for the prior-year three months. The decrease was primarily due to lower overall sales volume.

Six-Month Results
For the 2013 six-month period, IntriCon reported net sales of $25.6 million and a net loss of $(3.9) million, or $(0.69) per diluted share. This compares to 2012 net sales of $30.3 million and net income of $161,000, or $0.03 per diluted share. The six-month net loss from continuing operations was $(2.0) million, or $(0.35) per diluted share, with a discontinued operations net loss of $(1.9) million, or $(0.34) per diluted share.

As a percentage of total sales, hearing health stood at 39.9 percent, with medical and professional audio at 46.9 percent and 13.2 percent, respectively, for the six-month period. This compares to 45.5 percent, 40.5 percent and 14.0 percent for hearing health, medical and professional audio, respectively, in 2012.

Gross profit margins decreased to 22.0 percent from 26.6 percent for the prior-year six months. Again, the decrease was primarily due to lower overall sales volume. The company expects gross margins to strengthen in the second half of the year.

After adding back costs associated with non-recurring global restructuring expenses, non-cash charges for depreciation, amortization and stock-based compensation expense, the company reported a $(275,000) adjusted loss from continuing operations for the first half of the year. The table below reconciles certain financial measures used in this press release that were not calculated in accordance with generally accepted accounting principles, or GAAP, with the most directly comparable financial measure calculated in accordance with GAAP. IntriCon believes that this adjusted information is helpful in an analysis of its operating results by eliminating the non-recurring and non-cash items noted below.

The reconciliation of GAAP basis loss from continuing operations to adjusted loss from continuing operations for the six months ended June 30, 2013, is as follows:

(in $000s)   
GAAP basis loss from continuing operations$(1,993)
Non-recurring restructuring charges199
Depreciation and amortization1,254
Non-cash stock-based compensation265
Adjusted loss from continuing operations  $(275)

Business Update
Sales in IntriCon's medical business declined 20.9 percent from the prior-year period and 31.4 percent from 2013 first quarter. As previously reported, IntriCon had strong sales to Medtronic in the 2012 fourth quarter and 2013 first quarter, as Medtronic prepared for the launch of their MiniMed 530G insulin pump. The second-quarter decrease primarily stemmed from a reduction in sales to Medtronic as they await FDA approval of the MiniMed 530G. IntriCon expects medical sales to strengthen in the second half of the year.

Within cardiac, IntriCon remains on track to deliver initial orders for its wireless cardiac diagnostic monitor Sirona™ in the third quarter. Additionally, the company has made progress expanding its CDM sales and marketing infrastructure to further advance IntriCon's cardiac program and elevate its devices with market-demanded features.

Hearing health sales declined 19.5 percent over the prior-year quarter primarily due to the reduction in hi HealthInnovations orders and the continued softness in the conventional channel—which is consistent with industry trends. As previously indicated, IntriCon satisfied hi HealthInnovations' initial product ramp-up needs in the first half of 2012. While IntriCon continues to receive new orders from hi HealthInnovations, they have been substantially lower than the original ramp in the first half of 2012. As hi HealthInnovations further builds out its infrastructure, IntriCon continues to anticipate an order increase in the 2013 second half and remains very optimistic about the long-term prospects of this market-changing program.

Additionally, challenges remain in the conventional channel due to high device costs and inconveniences in the distribution channel. These dynamics are creating opportunities for alternative care models such as the insurance channel and the personal sound amplifier product (PSAP) market. To capitalize on these opportunities, IntriCon has hired an industry veteran to help spearhead the company's efforts in the value hearing aid (VHA) market. The company will be aggressively pursuing larger customers who can benefit from our value proposition.

Professional audio sales declined 37.5 percent from the prior-year period. The decrease was due the conclusion of the company's Singapore Government contract in December of 2012. With the company classifying portions of its professional audio business as discontinued, new growth is not anticipated going forward. However, IntriCon will leverage its core technology in professional audio to support existing customers, as well as pursue related hearing health and medical product opportunities.

Looking Ahead
Concluded Gorder, "We experienced significant challenges in the first half of 2013. However, as a company, we made the tough decisions necessary to better deploy our resources and aggressively drive our two largest growth opportunities: medical biotelemetry and value hearing health. We expect these to strengthen throughout the remainder of the year, and we're optimistic that we can achieve profitability by year-end."

Conference Call Today
As previously announced, the company will hold an investment community conference call today, Thursday, Aug. 8, 2013, beginning at 4:00 p.m. CT. Mark Gorder, president and chief executive officer, and Scott Longval, chief financial officer, will review second-quarter performance and discuss the company's strategies. To join the conference call, dial: 1-888-503-8169 and provide the conference ID number 1595266 to the operator.

A replay of the conference call will be available three hours after the call ends through 11:59 p.m. CT on Thursday, August 15, 2013. To access the replay, dial 1-888-203-1112 and enter passcode: 1595266.

About IntriCon Corporation
Headquartered in Arden Hills, Minn., IntriCon Corporation designs, develops and manufactures miniature and micro-miniature body-worn devices. These advanced products help medical, healthcare and professional communications companies meet the rising demand for smaller, more intelligent and better connected devices. IntriCon has facilities in the United States, Asia and Europe. The company's common stock trades under the symbol "IIN" on the NASDAQ Global Market. For more information about IntriCon, visit

Forward-Looking Statements
Statements made in this release and in IntriCon's other public filings and releases that are not historical facts or that include forward-looking terminology are "forward-looking statements" within the meaning of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be affected by known and unknown risks, uncertainties and other factors that are beyond IntriCon's control, and may cause IntriCon's actual results, performance or achievements to differ materially from the results, performance and achievements expressed or implied in the forward-looking statements. These risks, uncertainties and other factors are detailed from time to time in the company's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2012. The company disclaims any intent or obligation to publicly update or revise any forward-looking statements, regardless of whether new information becomes available, future developments occur or otherwise.



Consolidated Condensed Statements of Operations
(In Thousands, Except Per Share Amounts)
Three Months EndedSix Months Ended
June 30,June 30,June 30,June 30,





Sales, net$11,479$14,943$25,605$30,296
Cost of sales 9,617  11,174  19,974  22,227 
Gross profit1,8623,7695,6318,069
Operating expenses:
Sales and marketing7317541,6231,629
General and administrative1,3671,4352,9272,889
Research and development1,2491,0782,4782,161
Restructuring charges 199  -  199  - 
Total operating expenses 3,546  3,267  7,227  6,679 
Operating income (loss)(1,684)502(1,596)1,390
Interest expense(154)(180)(307)(359)
Equity in (loss) of partnerships(77)(13)(135)(37)
Other income (expense) (7) (9) 83  (57)
Income (loss) from continuing operations before income taxes and discontinued operations(1,922)300(1,955)937
Income tax expense 48  57  38  91 
Income (loss) before discontinued operations(1,970)243(1,993)846
Loss from discontinued operations, net of income taxes (1,473) (325) (1,921) (685)
Net income (loss)$(3,443)$(82)$(3,914)$161 
Basic income (loss) per share:
Continuing operations$(0.34)$0.04$(0.35)$0.15
Discontinued operations (0.26) (0.05) (0.34)


Net income (loss) per share:$(0.60)$(0.01)$(0.69)$0.03 
Diluted income (loss) per share:
Continuing operations$(0.34)$0.04$(0.35)$0.14
Discontinued operations (0.26) (0.05) (0.34)


Net income (loss) per share:$(0.60)$(0.01)$(0.69)$0.03 
Average shares outstanding:


Consolidated Condensed Balance Sheets
(In Thousands, Except Per Share Amounts)
June 30,December 31,



Current assets:
Restricted cash551563
Accounts receivable, less allowance for doubtful accounts of $106 at June 30, 2013 and $114 at December 31, 20126,2446,877
Other current assets1,1591,424
Current assets of discontinued operations 1,022  1,040 
Total current assets19,22320,560
Machinery and equipment33,42633,577
Less: Accumulated depreciation 28,321  27,578 
Net machinery and equipment5,1055,999
Investment in partnerships666773
Other assets, net9971,260
Other assets of discontinued operations 314  831 
Total assets$35,499 $39,132 
Current liabilities:
Checks written in excess of cash$444$637
Current maturities of long-term debt2,4492,945
Accounts payable4,4474,015
Accrued salaries, wages and commissions1,6141,644
Deferred gain110110
Other accrued liabilities2,2792,143
Liabilities of discontinued operations 235  173 
Total current liabilities11,57811,667
Long-term debt, less current maturities7,2647,222
Other postretirement benefit obligations582590
Accrued pension liabilities499510
Deferred gain220275
Other long-term liabilities 201  146 
Total liabilities20,34420,410
Commitments and contingencies
Shareholders' equity:
Common stock, $1.00 par value per share; 20,000 shares authorized; 5,702 and 5,687 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively5,7025,687
Read Full Story
Scroll to continue with content AD
  • DJI29348.1050.500.17%
    S&P 5003329.6212.810.39%
  • NIKKEI 22524101.2960.030.25%
    Hang Seng28984.77-71.65-0.25%
  • USD (PER EUR)1.110.00090.08%
    USD (PER CHF)1.03-0.0001-0.01%
    JPY (PER USD)110.170.02400.02%
    GBP (PER USD)1.30-0.0009-0.07%
More to Explore